For adult periodontitis. ANDA 65134, held by Sun Pharmaceutical Industries. Doxycycline Hyclate.
As of Nov 21, 2026, ANDA 65134 (Doxycycline Hyclate), held by Sun Pharmaceutical Industries, was first approved by FDA on May 13, 2005, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Doxycycline hyclate is indicated for use as an adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 13, 2005 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxycycline HyclateEQ 20MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
| Apr 1, 2025 | Supplement 22Labeling · Standard review | Approved | None posted |
| Jan 19, 2010 | Supplement 8Labeling | Approved | None posted |
| May 13, 2005 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters